Dr. Mikhael's primary research interest is in multiple myeloma and its related conditions (Waldenstrom's macroglobulinemia and amyloidosis).
He also pursues research in medical education, benign hematology and pharmacoeconomics:
- Multiple myeloma, Waldenstrom's and amyloidosis. Principal investigator of multiple clinical trials in both newly diagnosed and relapsed disease. Many of these trials include novel agents as well as combination therapies. He also has an interest in the growing field of quality-of-life in multiple myeloma.
- Medical education. Interested in models of teaching in medical education, including simulation techniques and novel tools for trainees.
- Benign hematology. Involved in national research efforts in novel agents for thrombosis. He also is involved in ITP research, mostly focused on novel agents such as thrombopoietins.
- Pharmacoeconomics. Interested in the cost of cancer care — developing appropriate models to account for the cost of care and validate therapies on their cost-effectiveness.